Allergan Still Undervalued as Likelihood of Pfizer Deal Fades
April 05, 2016 at 10:00 AM EDT
New rules from the U.S. Treasury may put a damper on the Pfizer merger, but Allergan remains an attractively priced wide-moat company nonetheless.